vida: extract claims from 2026-04-28-phti-employer-glp1-coverage-behavioral-mandate-2025

- Source: inbox/queue/2026-04-28-phti-employer-glp1-coverage-behavioral-mandate-2025.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 5
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-market-stratification-access-first-vs-clini
 scope: structural
 sourcer: Vida synthesis
 supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "the-healthcare-attractor-state-is-a-prevention-first-system-where-aligned-payment-continuous-monitoring-and-ai-augmented-care-delivery-create-a-flywheel-that-profits-from-health-rather-than-sickness"]
-related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "the-healthcare-attractor-state-is-a-prevention-first-system-where-aligned-payment-continuous-monitoring-and-ai-augmented-care-delivery-create-a-flywheel-that-profits-from-health-rather-than-sickness", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
+related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "the-healthcare-attractor-state-is-a-prevention-first-system-where-aligned-payment-continuous-monitoring-and-ai-augmented-care-delivery-create-a-flywheel-that-profits-from-health-rather-than-sickness", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt"]
 ---
 
 # GLP-1 behavioral support market stratifies by physical integration level with atoms-to-bits companies achieving profitability while behavioral-only companies fail
@@ -24,3 +24,10 @@ The GLP-1 behavioral support market has stratified into four distinct tiers with
 **Source:** Huang et al. 2025, Nicholas Thompson/CNBC 2026
 
 LLM coaching research shows that message-level behavioral support can be replicated by AI after refinement (82% helpfulness parity with human coaches), but clinical equivalence requires privacy, bias, and safety infrastructure that LLMs cannot provide. This confirms that behavioral-only offerings are commoditizable, while physical integration (CGM, prescribing, clinical monitoring) creates the defensible layer. The $1.8B, 2-person AI telehealth startup demonstrates complete commoditization of pure prescribing, but its FDA warnings and fraud lawsuits show that clinical oversight cannot be automated away.
+
+
+## Extending Evidence
+
+**Source:** PHTI December 2025 report on UHC Total Weight Support program
+
+UHC requires Real Appeal Rx or WeightWatchers as coverage prerequisites, but WeightWatchers filed bankruptcy in 2024. This creates a structural contradiction: the mandated behavioral vendor is no longer viable, forcing UHC to either rebuild the behavioral layer in-house or switch to a competitor. This validates the atoms-to-bits integration thesis—behavioral-only companies cannot survive as mandated infrastructure.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -72,3 +72,10 @@ The $1.8B, 2-person AI-staffed GLP-1 telehealth startup demonstrates that low-en
 **Source:** PHTI December 2025 employer report citing Prime Therapeutics
 
 Prime Therapeutics data cited in PHTI report confirms only 1-in-12 patients (8.3%) remain on therapy after three years, which is even lower than the 14% year-two ceiling. This provides independent corroboration from a major PBM dataset.
+
+
+## Supporting Evidence
+
+**Source:** PHTI December 2025 report, Prime Therapeutics data
+
+Prime Therapeutics data cited by PHTI shows 1-in-12 (8.3%) persistence at three years, which is even lower than the 14% year-two ceiling previously documented. This extends the persistence decay curve and strengthens the case that real-world adherence is the binding constraint on GLP-1 population health impact.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-icer-glp1-affordable-access-2025.md
 scope: structural
 sourcer: ICER
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
-related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
+related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
 ---
 
 # GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
@@ -31,3 +31,10 @@ Employer response to GLP-1 cost pressure includes cost management strategies: st
 **Source:** on/healthcare.tech, Evernorth EncircleRx operational data
 
 Evernorth EncircleRx reports ~$200 million saved since 2024 across 9 million enrolled lives through 15% cost cap or 3:1 savings guarantee structure. This represents early evidence that managed-access infrastructure can contain costs, though the $200M savings across 9M lives (~$22/member) is modest relative to the 10x PMPM increase that created the fiscal pressure.
+
+
+## Supporting Evidence
+
+**Source:** PHTI December 2025 employer survey data
+
+59% of employers report GLP-1 utilization exceeding expectations, 66% report significant spending impact, and 77% of large employers say managing GLP-1 costs is 'extremely or very important' for 2026. This confirms the fiscal pressure is not abating despite managed-access infrastructure deployment.

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infr
 scope: structural
 sourcer: on/healthcare.tech
 challenges: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
-related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression"]
 ---
 
 # Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
@@ -39,3 +39,10 @@ But the structural challenge is real: if manufacturers can profitably deliver GL
 **Source:** PHTI December 2025 employer report
 
 Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships across 15+ program administrators (GoodRx, Teladoc, Calibrate, Form Health, Waltz). Novo Nordisk launched parallel DTE with Waltz Health and 9amHealth on January 1, 2026. Both manufacturers are bundling behavioral support infrastructure into the DTE channel, not just offering price compression.
+
+
+## Supporting Evidence
+
+**Source:** PHTI December 2025 report on manufacturer direct-to-employer programs
+
+Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships across 15+ program administrators (GoodRx, Teladoc, Calibrate, Form Health, Waltz). Novo Nordisk launched parallel DTE channel January 1, 2026 with Waltz Health and 9amHealth. This confirms manufacturer DTE is not a pilot but a structural channel shift happening simultaneously across both major GLP-1 manufacturers.

inbox/queue/2026-04-28-phti-employer-glp1-coverage-behavioral-mandate-2025.md

@@ -1,85 +0,0 @@
----
-type: source
-title: "PHTI Employer Approaches to GLP-1 Coverage — Market Trend Report December 2025"
-author: "Peterson Health Technology Institute"
-url: https://phti.org/employer-approaches-to-glp1-coverage/
-date: 2025-12-15
-domain: health
-secondary_domains: []
-format: report
-status: unprocessed
-priority: high
-tags: [GLP-1, employer-benefits, payer-mandates, behavioral-support, value-based-care, adherence]
-intake_tier: research-task
----
-
-## Content
-
-PHTI (Peterson Health Technology Institute) published this market trend report in December 2025 as an employer purchasing guide for GLP-1 coverage and virtual solutions.
-
-Key statistics from the report and corroborating sources:
-
-**Employer coverage rates:**
-- 43% of firms with 5,000+ workers now cover GLP-1s for weight loss (up from 28% in 2024)
-- Nearly half of all respondents (48%) covered GLP-1s for weight loss
-- 89% of covering employers plan to continue coverage over the next 1-2 years
-- 59% report utilization exceeding expectations; 66% report significant spending impact
-- 77% of large employers say managing GLP-1 costs is "extremely or very important" for 2026
-
-**Behavioral support mandates — the headline finding:**
-- 34% of firms covering GLP-1s now require dietitian, case management, therapy, or lifestyle participation as a coverage condition (up from 10% the prior year — a 3.4x jump in one year)
-- 38% of employers require lifestyle behavior program participation as a condition of coverage (figure varies by survey)
-- 79% of large employers have expanded utilization management despite flat obesity-indication coverage
-
-**Payer programs implementing behavioral support:**
-- **Evernorth EncircleRx**: Manages 9 million enrolled lives with a 15% cost cap or 3:1 savings guarantee; has saved plans approximately $200 million since 2024; added $200 copay cap on Wegovy and Zepbound in 2025
-- **Optum Rx Weight Engage**: Pairs GLP-1 access with obesity specialist navigation, coaching, and lifestyle programs
-- **UHC Total Weight Support**: Requires coaching engagement (Real Appeal Rx or WeightWatchers) as a coverage prerequisite
-
-**Adherence data (corroborated from additional sources):**
-- Meta-regression: ~50% discontinuation within one year; ~60% weight regain within 12 months of cessation
-- Prime Therapeutics data (cited by Mercer): Only 1-in-12 patients remain on therapy after three years
-
-**CMS/Medicare:**
-- Weight-loss coverage begins in May 2026 for Medicaid and January 2027 for Medicare Part D
-- CMS "bridge program" enabling GLP-1 access for Medicare Part D by July 2026
-- CMS model supplements coverage with "lifestyle support programs" at no cost
-
-**Manufacturer direct-to-employer channels (as of early 2026):**
-- **Eli Lilly Employer Connect (March 5, 2026)**: Direct employer channel at $449/dose Zepbound; partnerships with 15+ program administrators including GoodRx, Teladoc, Calibrate, Form Health, Waltz
-- **Novo Nordisk**: Parallel DTE play with Waltz Health and 9amHealth (launched January 1, 2026)
-
-**The structural shift:**
-Traditional yes/no formulary decisions cannot accommodate GLP-1 economics (36.2M eligible commercially insured adults × $1,000-1,200/month). Payers and employers are building "managed-access operating systems" covering: which populations qualify, through which channels, with what behavioral gates, at what subsidy levels, and with what discontinuation rules.
-
-Infrastructure opportunities identified:
-- Utilization management infrastructure
-- Outcomes-based contracting frameworks
-- Indication-specific cardiometabolic programs (cardiovascular disease, OSA, MASH, perimenopause, prediabetes)
-- Adherence, tapering, and discontinuation management systems
-- Employer-side financing or subsidy products
-
-## Agent Notes
-
-**Why this matters:** The 34% → behavioral mandate rate (up from 10%) in one year is structural acceleration of a key claim from the Session 29 branching point. This confirms that behavioral support is becoming payer-mandated infrastructure, not consumer-optional. The payer response (Evernorth, Optum Rx, UHC all building behavioral support as prerequisite) validates that the market is moving exactly as Belief 4 predicts — the software coaching layer creates margin only when bundled with the physical drug delivery.
-
-**What surprised me:** The "managed-access operating system" framing. The payer response to GLP-1s is not just formulary addition — it's building infrastructure that functions like an operating system for drug access. This is bigger than I expected. The infrastructure layer (utilization management, adherence systems, indication-specific programs) is a distinct opportunity from the behavioral coaching layer.
-
-**What I expected but didn't find:** A clear winner among the payer-behavioral support vendor partnerships. UHC requires Real Appeal Rx or WeightWatchers — but WeightWatchers just filed bankruptcy. This creates a fascinating gap: the mandated vendor is no longer viable in its pre-bankruptcy form.
-
-**KB connections:**
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — challenged by adherence data; the managed-access OS framing adds complexity: the infrastructure investment may actually enable higher persistence, partially recovering the inflationary trajectory
-- [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — payer behavioral support mandates are a NEW mechanism for value-based care at the formulary level
-- [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
-
-**Extraction hints:**
-- CLAIM: "GLP-1 payer behavioral mandates tripled in one year (10% → 34%) signaling structural shift from drug-only formulary to managed-access operating systems" — confidence: likely
-- CLAIM: "The GLP-1 managed-access infrastructure layer (utilization management, adherence systems, indication-specific programs) creates a distinct platform opportunity separate from behavioral coaching" — confidence: experimental
-- UPDATE: Challenged_by annotation for "chronic use model inflationary through 2035" claim — real-world persistence is 1-in-12 at 3 years; managed-access infrastructure partially compensates
-
-**Context:** PHTI is a credible, nonprofit health technology evaluator. December 2025 publication makes this current. The onhealthcare.tech piece (same URL batch) provides complementary analysis from a market strategy lens.
-
-## Curator Notes
-PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
-WHY ARCHIVED: First direct evidence that behavioral mandates have become structural (not optional) in employer GLP-1 coverage — the 34% mandate rate (up from 10%) is the inflection signal
-EXTRACTION HINT: Focus on the mandate rate acceleration and the managed-access operating system framing — these are the novel claims; the adherence statistics are confirmatory of existing KB claims